Treatment of autoimmune disorders using chimeric antigen receptor therapy
AssigneeNovartis AG
InventorsBambang Adiwijaya, Thomas Calzascia, Peter Gergely, David Scott Pearson, Martin Stangel
Life of this patent
Estimating the term…
Abstract
The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods, and therapeutic uses thereof for treating autoimmune diseases or disorders.
Claims20
A method of treating systemic lupus erythematosus (SLE) in a human subject, the method comprising administering to the subject a population of T cells that express, or comprise a nucleic acid configured to express, a CD19 chimeric antigen receptor (CAR) at a dose of 0.5-50×106 viable CAR+ T cells, wherein the CAR comprises a CD19 binding domain, a transmembrane domain and an intracellular signaling domain.
A method of treating a subject having an autoimmune disease or disorder, the method comprising:
- (I) administering to the subject a population of cells that express, or comprise a nucleic acid configured to express, a CD19 CAR, wherein the population of cells was made by a method comprising:
- (i) contacting a population of cells with an agent that stimulates a CD3/TCR complex or an agent that stimulates a costimulatory molecule on the surface of the cells;
- (ii) contacting the population of cells with a nucleic acid molecule encoding the CAR, thereby providing a population of cells comprising the nucleic acid molecule;
- and
- (iii) harvesting the population of cells for storage or administration,
- wherein step (ii) is performed together with step (i) or no later than 20 hours after the beginning of step (i), and step (iii) is performed no later than 30 hours after the beginning of step (i);
- or
- (II) administering to the subject rapcabtagene autoleucel.
A method of making a population of cells that express a CAR, the method comprising:
- (i) contacting a population of cells with an agent that stimulates a CD3/TCR complex or an agent that stimulates a costimulatory molecule on the surface of the cells, wherein the population of cells is from a subject having an autoimmune disease or disorder;
- (ii) contacting the population of cells with a nucleic acid molecule encoding the CAR, thereby providing a population of cells comprising the nucleic acid molecule;
- and
- (iii) harvesting the population of cells for storage or administration,
- wherein step (ii) is performed together with step (i) or no later than 20 hours after the beginning of step (i), and step (iii) is performed no later than 30 hours after the beginning of step (i).
Dependencies are inferred from the claim text.